CA4 and cancer: CA-4P is a water-soluble prodrug of CA-4, and CA-4P is undergoing Phase II and III clinical trials to evaluate the safety and efficacy in human cancer patients when used in combination with chemotherapy or radiation therapy.35, 36, 37 In this study, we showed that a combination of CQ could potentiate antitumor effects of CA-4.